Chinese genome editing startup EdiGene Inc has secured 400 million yuan ($61.7 million) in a Series B+ round of financing led by private equity (PE) firm Loyal Valley Capital to advance its pipeline into clinics and to scale up the business operation.
Start your deal-making journey now!
Subscribe now to enjoy unlimited access at just $59.
Premium coverage on private equity, venture capital, and startups in Asia.
Exclusive scoops from our reporters in nine key markets.
In-depth interviews with industry leaders shaping the ecosystem.
Already a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com